We report the successful establishment of seven human medullary thyroid carcinomas (MTC) as continuous cell lines. Characteristic features--such as the presence of neuroendocrine granules--and the positive immunoreactivity to antibodies to CT, CGRP, GRP, SRIF, 5-HT, NSE, PHE, LK2H10, ER and Pgr were followed throughout the cultivation. An overexpression of the antiapoptotic gene bcl-2 was detected in the cell lines. Deregulation of apoptosis plays an important role in multistep tumorigenesis. MTCs are known for the phenomenon of bcl-2-based chemo- and radioresistance. Our studies focus on influencing the growth rates and modulating the apoptotic rates by treatment with proliferation-modifying substances and anticancer drugs. Our MTC cell lines are useful models for these in vitro studies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
miRNA-541-5p regulates myocardial ischemia-reperfusion injury by targeting ferroptosis.
J Cardiothorac Surg
January 2025
The First Hospital of Lanzhou University, Lanzhou, China.
Background: This article aims to use high-throughput sequencing to identify miRNAs associated with ferroptosis in myocardial ischemia-reperfusion injury, select a target miRNA, and investigate its role in H9C2 cells hypoxia-reoxygenation injury.
Methods: SD rats and H9C2 cells were used as subjects. ELISA kits quantified MDA, SOD, GSH, LDH, and ferritin levels.
TOM40 as a prognostic oncogene for oral squamous cell carcinoma prognosis.
BMC Cancer
January 2025
Department of Otorhinolaryngology, Shenzhen Key Laboratory of Otorhinolaryngology, Longgang Otorhinolaryngology Hospital, Shenzhen Institute of Otorhinolaryngology, No. 3004 Longgang Avenue, Shenzhen, Guangdong, China.
Background: To investigate the role of the translocase of the outer mitochondrial membrane 40 (TOM40) in oral squamous cell carcinoma (OSCC) with the aim of identifying new biomarkers or potential therapeutic targets.
Methods: TOM40 expression level in OSCC was evaluated using datasets downloaded from The Cancer Genome Atlas (TCGA), as well as clinical data. The correlation between TOM40 expression level and the clinicopathological parameters and survival were analyzed in TCGA.
Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study.
Ann Hematol
January 2025
Hematology Unit, Hospital Universitari i Politècnic La Fe, Valencia, España.
There is a limited information available on the clinical characteristics, treatment patterns and outcomes on older patients diagnosed with Acute Myeloid Leukemia (AML) in Latin-America. This multicenter retrospective study analyzed 269 patients over 60 years of age diagnosed with AML in Colombia, using data from RENEHOC-PETHEMA registry, from 2009 to 2023. The median age at diagnosis was 70 years (Range:60-98), 55% were men, 61% had an ECOG < 2, and 75.
View Article and Find Full Text PDFA Neuron-Like Cellular Model for Severe Tinnitus Associated with Rare Variations in the ANK2 Gene.
Mol Neurobiol
January 2025
Otology & Neurotology Group CTS495, Division of Otolaryngology, Department of Surgery, Instituto de Investigación Biosanitaria, Ibs.GRANADA, Granada, Universidad de Granada, Granada, Spain.
Tinnitus is the perception of sound without an external source, often associated with changes in the auditory pathway and different brain regions. Recent research revealed an overload of missense variants in the ANK2 gene in individuals with severe tinnitus. ANK2, encoding ankyrin-B, regulates axon branching and inhibits microtubule invasion.
View Article and Find Full Text PDFDonor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Nat Med
January 2025
Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Allogeneic chimeric antigen receptor (CAR) T cells targeting disialoganglioside-GD2 (ALLO_GD2-CART01) could be a therapeutic option for patients with relapsed or refractory, high-risk neuroblastoma (r/r HR-NB) whose tumors did not respond to autologous GD2-CART01 or who have profound lymphopenia. We present a case series of five children with HR-NB refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting. Four of them had previously received allogeneic hematopoietic stem cell transplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!